Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Ladiratuzumab-Vedotin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seattle Genetics
- 26 Apr 2018 According to a Seattle Genetics media release, first patient has been treated in this trial.
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.
- 13 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.